Artwork
iconShare
 
Manage episode 507854074 series 2739469
Content provided by Ben Comer. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ben Comer or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

We love to hear from our listeners. Send us a message.

On this week's episode, Joel Latham, President and CEO at Incannex Healthcare, talks about developing cannabinoid and psychedelic combination therapies for conditions as diverse as sleep apnea, rheumatoid arthritis, and generalized anxiety disorder. Joel walks through his funding strategy for the publicly-traded company, his desire to lead in a new category of medicine, and what comes next.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

  continue reading

Chapters

1. Introduction to Joel Latham and Incanix (00:00:00)

2. From Rugby to Business Leadership (00:08:10)

3. Pivoting from Dental to Novel Therapies (00:11:40)

4. Sleep Apnea Treatment Development (00:18:30)

5. Rheumatoid Arthritis Combination Therapy (00:30:20)

6. Psychedelic Therapy for Anxiety Disorder (00:37:10)

7. Manufacturing Challenges with Controlled Substances (00:45:10)

8. Funding Strategy and Shareholder Value (00:48:20)

9. Moving from Australia to NASDAQ (00:53:00)

276 episodes